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Artemisinin derivatives are now the most potent and rapidly acting antimalarials. The aim of this study was to assess the in vivo
eﬃcacy and tolerability of a combination of Malartin (an artesunate) and sulphadoxine-pyrimethamine (SP) in the treatment of
uncomplicated falciparum malaria in Dibanda, Cameroon. A total of 197 subjects were recruited into the study and administered
Malartin for 3 days and SP as a single dose on day 0. Only 174 of the subjects were successfully followed up on days 3, 7, and 14.
The overall success rate of the drug combination was 92.53%. Parasite density decreased during the follow-up period in diﬀerent
age groups, sexes, and social classes. The prevalence of anaemia decreased from 22.99% at enrolment to 9.77% on day 14, and the
diﬀerence was signiﬁcant (P<0.05) on all days of followup. The drug combination did not give rise to any serious side eﬀects.
1.Introduction
Malaria continues to be a debilitating disease with public
health consequences on an ailing population that is already
poor [1]. Many malaria control strategies exist, but none
is appropriate and aﬀordable in all contexts, especially in
endemic areas. The World Health Organization (WHO) [2]
recommends three essential elements of malaria control,
namely, the application of vector control, early detection,
or forecasting of epidemics, and early diagnosis and prompt
treatment of the disease.
Plasmodium falciparum is the main infecting species and
its infections can be very fatal unless promptly treated. It
is responsible for the majority of deaths due to malaria
and the situation has been worsened by the development
of resistance by this parasite to most antimalarial drugs
[3]. Resistance to antimalarial drugs arises as a result of
spontaneously occurring mutations that aﬀect the structure
and activity at the molecular level of the drug target in the
malaria parasite or aﬀect the access of the drug to that target
[4]. Drug resistance has been implicated in the spread of
malaria to new areas and reemergence of malaria in areas
where the disease had been eradicated resulting in increased
morbidity and mortality [5]. Hence it is important to ensure
a rational use of the few remaining eﬀective drugs in order to
maximize their useful therapeutic life without sacriﬁcing the
safe, eﬀective, accessible, and aﬀordable treatment of those at
risk. As such there has been a reexamination of the potential
of combinations of existing products and the development
of new drug combinations. The WHO [4] now recommends
the use of artemisinin-based combination therapies (ACTs)
for the ﬁrst-line treatment of P. falciparum in endemic2 Journal of Tropical Medicine
areas, since resistance may be delayed or prevented by using
combinations of drugs with independent modes of action
and diﬀerent biochemical targets in the parasite. Artemisinin
or one of its derivatives is usually used with one or more
other longer acting partner drug(s) in a treatment regimen
that can protect against recrudescent infections. The rapid
onset of action of artemisinins reduces the biomass of the
parasite within a short period of time and the remaining
parasites are eliminated by the longer-acting partner drug
[4]. Cameroonian health authorities adopted this WHO
policy for the treatment of uncomplicated malaria in 2004.
The artesunate, Malartin, (Kakwa Biofarm) was recently
introduced into the Cameroon market and its eﬃcacy
alone and in combination with amodiaquine has been
reported elsewhere [6]. Since its introduction into the mar-
ket malartin’s eﬃcacy in combination with sulphadoxine-
pyrimethamine (SP) has not yet been done in the Cameroo-
nian population against uncomplicated falciparum malaria.
Althoughthemalartin/amodiaquinecombinationiseﬀective
in eliminating parasites, many patients, however, complain
about the side eﬀects of the amodiaquine component of the
drugcombination.Thereisthereforeaneedtoevaluateother
combinations with malartin in the Cameronian population
in order to know the best combination that is most
eﬃcacious and safe. This study was therefore undertaken
to assess the eﬃcacy and tolerability of a combination of
Malartin and SP against uncomplicated P. falciparum in
Dibanda, Southwest Cameroon.
2.MaterialsandMethods
2.1.StudySite. ThisworkwascarriedoutinDibandavillage,
southwest Cameroon. The centre for recruiting and treating
patients was the Cameroon Christian Medical Foundation
(CAMEF). Dibanda has a population of about 3500 people
and is located on the eastern slope of Mount Cameroon,
where the dense equatorial forest has been cleared. Weather
records from the Cameroon Development Corporation
indicate a mean relative humidity of 83.1%, temperature
rangeof18◦Ct o35 ◦Candanannualrainfallof4000mm[7].
There is intense and perennial P. falciparum transmission in
the area.
2.2. Study Patients. The study was carried out between
December 2007 and August, 2008. Patients who presented
withsignsandsymptomsofmalariaatCAMEFwerereferred
to members of the research team after consultation. The
reason for the study was explained to them before asking for
their written informed consent. Participants were eligible for
inclusion into the study if they were ≥1 year, diagnosed with
monoinfections of uncomplicated P. falciparum malaria,
parasitaemia ≥1000 asexual parasites/μL blood, absence of
concomitant illness, and written informed consent by the
patient or legal guardian in the case of minors. Those
excluded from the study were all participants who took
antimalarial drugs in the previous 48 hours, pregnant and
lactating women, those with severe malaria or any danger
signs as deﬁned by the WHO or mixed infections of
plasmodia, and those who refused to participate in the study.
Voluntary withdrawal, development of severe manifestations
following therapy and overt toxicity (hypersensitivity) to
the drugs were considered reasons enough for withdrawing
patients from the study. They were then treated with oral
quinine (25mg body weight per day for 5 days). An ethical
clearance for this work was obtained from the Ethical Review
Committee of the Delegation of Public Health, South West
Region, Cameroon. Overall, 576 patients were screened,
amongst whom 197 were eligible for inclusion in the study.
2.3. Collection and Processing of Blood Samples. Before blood
collection, demographic data such as age, gender, social
class (poor class—those who lived in plank houses, used
pit toilets, and were either unemployed or subsistence
farmers with no steady income; middle class—those who
lived in cement block houses, used ﬂush toilets, and had
basic amenities such as television, refrigerator and radio,
and earned a steady monthly salary; rich class—those who
had all what the middle class individuals had or more
as well as a car), weight, prior use of antimalarial drugs,
and clinical manifestations were recorded. Blood samples
were obtained through a ﬁnger prick for the preparation of
thick and thin blood ﬁlms and determination of packed cell
volume (PCV). Blood ﬁlms were Giemsa-stained according
to the method of Cheesbrough [8] and observed for malaria
parasites using the oil immersion (x100) objective of the
microscope. The thick ﬁlms were used to determine the
levels of parasite density by counting the asexual forms of
parasites found per 200 white blood cells (WBC) assuming
a WBC count of 8,000WBC/μL blood [8]. This was used
to calculate the geometric mean parasite density (GMPD).
Slides were considered negative if no parasites were seen
in 100 high-power ﬁelds of the microscope. The thin ﬁlms
were used to check that the malaria parasites detected were
monoinfections of P. falciparum [8]. In order to double-
check the results, slides were examined by two experienced
microscopists independently.
2.4. Determination of Packed Cell Volume (PCV). Blood-
ﬁlled capillary tubes were spun at 12,000g for 5 minutes
and PCV values were read using a PCV reader. Patients were
considered to be anaemic if PCV values were <31%.
2.5.TreatmentandFollowupofParticipants. Eachpatientwas
treated with 4mg/Kg body weight/day of malartin on days
0, 1, and 2 and 25mg/kg body weight of sulphadoxine and
1.25mg/Kg body weight of pyrimethamine in a single dose
[4].Theﬁrstdoseofthedrugswasadministeredunderdirect
supervision and patients were observed for 30 minutes for
vomiting and allergic reactions to the drugs. If a patient
vomited the treatment was repeated. If vomiting persisted,
the patient was withdrawn from the study and placed on
quinine therapy. The day of sampling was termed day 0.
Patients were told to come back to the clinic on days 3,
7, and 14 for followup. The side eﬀects experienced by the
patients were recorded, on days of followup, and they were
encouraged to return at any time they felt ill or in case of
clinical deterioration. All the individuals who failed to come
back on subsequent appointment days were visited at home.Journal of Tropical Medicine 3
In cases where the patients could not be located at all, they
were excluded from the study.
The blood of the patients was collected on all days
of followup to determine their parasite density and PCV
levels. Study participants were considered to have attained
a study endpoint whenever there was onset of symptoms
requiring alternative drugs and/or hospitalization, receipt
of another antimalarial from outside the study team, or
voluntary withdrawal. Participants still parasitaemic on day
14 were referred for alternative treatment.
2.6. Safety Assessment. Any signs and symptoms that ﬁrst
occurred or became more severe after treatment were
considered to be the adverse eﬀects of treatment and were
recorded during the course of followup.
2.7. Therapeutic Endpoints. Treatment outcome was classi-
ﬁed as early treatment failure (ETF), late clinical failure
(LCF), late parasitological failure (LPF), or adequate clinical
andparasitological response (ACPR),according to the WHO
[9] criteria albeit with a day 14 endpoint instead of a day 42.
(i) To be categorized as an ETF, a patient had to show
danger signs or severe malaria on days 1, 2, or 3, in the
presence of parasitaemia; a day 2 parasitaemia that was
greater than the day 0 (irrespective of axillary temperature);
a parasitaemia on day 3, with fever (an axillary temperature
of at least 37.5◦C); or a day 3 parasitaemia that was at least
25% of the day 0.
(ii) To qualify as LCF, the patient had to show danger
signs or severe malaria, in the presence of parasitaemia, on
any day after day 4 and before day 14, without previously
meeting any of the ETF criteria; or fever in the presence of
parasitaemia on any day between day 4 and day 14, without
previously meeting any of the ETF criteria.
(iii) Any patient found parasitaemic between day 4
a n dd a y1 4 ,b u tw i t hat e m p e r a t u r eo f<37.5%, without
previously meeting any of the criteria of ETF or LCF, was
considered as an LPF.
(iv) All other patients who were aparasitaemic on day 14,
irrespective of axillary temperature, were considered ACPR.
2.8. Statistical Analysis. The data were analyzed using
Microsoft Excel 2002 and SPSS version 10. Students’ t-test or
analysisofvariance(ANOVA)wasusedtotestthediﬀerences
between the treatment means. The chi square test or Fisher’s
exact χ2 was used for comparisons of the cure rates. The level
of signiﬁcance was set at P<0.05.
3. Results
3.1. Baseline Characteristics of Patients. Overall, 576 people
a g e d1t o7 8y e a r sw e r es c r e e n e da n dat o t a lo f1 9 7p a r -
ticipants satisﬁed the enrolment criteria and were included
in the study. Twenty-three patients were lost in the course
of followup. A total of 174 participants were successfully
followed up (74 males and 100 females). The median age was
11.4 (Table 1). Overall, 78.16% (136/174) of the participants
were of the poor class while there were 32 and 6 patients in
the middle and rich classes, respectively.
Table 1: Baseline characteristics of patients attending Cameroon
Christian Medical Foundation (CAMEF) during the in vivo study,
2007-2008.
Characteristic Value
Number of study subjects 174
Sex ratio (male/female ratio) 74/100
Age (median) 11.4
Age of males (median) 11.8
Age of females (median) 10.9
Body weight (kg) (mean ± SD) 40.40 ±21.90 (9–95)∗
Initial body temperature (◦C)
(mean ± SD) 37.91 ±0.93 (36–40)∗
Haematocrit (%) (mean ± SD) 34.27 ±5.64 (13–50)∗
% anaemic (PCV < 31%) 22.99% (40/174)
Geometric mean parasite density 4338 ±11725
(1000–104000)∗
∗Indicates the range. SD = standard deviation.
Table 2: Clinical outcome of patients attending CAMEF during the
in vivo study, 2007-2008 after treatment with Malartin and SP.
Parameter Clinical outcome
ACPR 92.53% (161)
ETF 0.60% (01)
LCF 03.45% (06)
LPF 03.45% (06)
Clinical treatment failure 07.50% (13)
3.2. Assessment of Drug Eﬃcacy. The adequate clinical and
parasitological response (ACPR) rate on day 14 was 92.53%
(161/174). The early treatment failure (ETF) rate was 0.60%
(01/174), while the late clinical failure (LCF) and late
parasitological failure (LPF) rates were 03.45% (06/174) and
03.45% (06/174), respectively. Overall, the clinical treatment
failure rate was 07.50% (Table 2).
3.3.Variationin Geometric MeanParasiteDensitywithrespect
to Sex, Age, and Social Class of Patients. There was a steady
decreaseinGMPDinbothsexesfromday0today14,butthe
diﬀerence was insigniﬁcant except on day 7 (Table 3) when
the GMPD in males was signiﬁcantly higher than that in
females (χ2 = 4.826, P = 0.03). GMPD decreased steadily
in all age groups from day 0 to day 14 following treatment
(Table 3), but the diﬀerence was only signiﬁcant on day 0
(F = 3.667, P = 0.014). There was no signiﬁcant diﬀerence
in GMPD across the diﬀerent social classes during followup
after treatment with Malartin and SP (Table 3).
3.4. The Eﬀect of Malaria Parasitaemia on Anaemia Status
during Followup. At enrolment, 22.99% (40/174) of the
participants were anaemic and had a higher GMPD when
compared with the nonanaemic subjects (Table 4). This
GMPD was observed to decrease steadily from day 0 to day
14. There was no signiﬁcant diﬀerence in GMPD between
the two groups, except on day 0 when the diﬀerence was
signiﬁcant (χ2 = 6.528, P = 0.002).4 Journal of Tropical Medicine
Table 3: Variation in geometric mean parasite density of patients attending CAMEF during the in vivo study, 2007-2008 by sex, age group,
and social class during followup after treatment with Malartin and SP.
Characteristic GMPD
Category Day 0 Day 3 Day 7 Day 14
Sex Male N = 74 4599 (1014–04000) 2199 (382–5846) 900 (207–4938) 808 (280–3749)
Female N = 100 4154 (1000–42974) 1904 (196–10667) 641 (143–4525) 626 (167–3574)
Level of signiﬁcance F = 1.418
P = 0.235
F = 0.625
P = 0.430
F = 4.826
P = 0.030
F = 0.764
P = 0.386
Age group (years)
1–5 (N = 49) 6517 (1087–48511) 2189 (196–5846) 788 (181–3629) 751 (170–3749)
6–10 (N = 33) 3820 (1067–104000) 1652 (203–7719) 608 (182–1920) 604 (475–776)
11–15 (N = 24) 4054 (1200–18316) 2424 (333–7385) 832 (207–2913) 613 (167–2222)
>15 (N = 68) 3524 (1000–36596) 1975 (218–10667) 730 (143–4938) 692 (150–3176)
Level of signiﬁcance F = 3.667
P = 0.014
F = 1.232
P = 0.300
F = 0.740
P = 0.540
F = 1.143
P = 0.342
Social class
Poor class (N = 136) 4495 (1000–48511) 2021 (203–10667) 727 (143–4938) 854 (167–3749)
Middle class (N = 32) 4238 (1014–104000) 2239 (196–15846) 838 (385–2939) 746 (350–3176)
Rich class (N = 06) 2193 (1023–5500) 822 (406–2016) 353 (353–353) 0
Level of signiﬁcance F = 0.793
P = 0.454
F = 1.315
P = 0.272
F = 0.282
P = 0.755
F = 0.234
P = 0.792
Table 4: Eﬀect of parasitaemia on anaemia in patients attending CAMEF during the in vivo study, 2007-2008 following treatment with
Malartin and SP.
Status
GMPD (range)
Day 0 Day 3 Day 7 Day 14
Anaemic 5948 (1037–104000) 1974 (196–15846) 690 (181–2667) 598 (340–2222)
Non anaemic 3710 (1000–48511) 2005 (203–10667) 747 (143–4938) 624 (167–3749)
Level of signiﬁcance F = 6.528
P = 0.002
F = 0.954
P = 0.388
F = 0.745
P = 0.477
F = 1.963
P = 0.152
3.5. Prevalence of Anaemia in the Diﬀerent Age Groups.
77.01% (134/174) of participants were not anaemic at enrol-
ment. Anaemia was generally more prevalent in children
(<15years)thaninadults(≥15years),andthediﬀerencewas
signiﬁcant (P<0.05) on all days of followup (Table 5). The
proportion of anaemic subjects (both children and adults)
decreased from 22.9% on day 0 to 9.77% on day 14 and the
diﬀerence was signiﬁcant (χ2 = 10.41, P = 0.034).
3.6. Prevalence of Anaemia in the Diﬀerent Social Classes.
Overall, anaemia was more prevalent in the middle class,
and generally decreased gradually in all the diﬀerent social
classes after treatment with Malartin and Fansidar. On day
14,thehighestprevalence(10.30%)wasrecordedinthepoor
class. There was no signiﬁcant diﬀerence in the prevalence of
anaemia across the diﬀerent social classes during followup
after treatment with Malartin and Fansidar (P>0.05).
3.7. Variation of Body Temperature during Followup. It was
observed that after administering malartin and SP to the
subjects, their body temperatures reduced rapidly and fever
clearance on day 3 was 97.00%. Variation of body temper-
ature during followup was done by comparing the mean
temperature on day 0 with that of the rest of the followup
days (data not shown). The mean body temperature on day
0( 3 7 .91 ± 0.93) was signiﬁcantly higher than that of day 14
(37 ±0.08) (F = 53.10, P = 0.001).
3.8. Assessment of Drug Safety during Followup. At o t a lo f
40 out of 174 subjects experienced side eﬀects, and fatigue
(25.00%), fever (22.50%), and dizziness (17.50%) were the
most prevalent side eﬀects. These side eﬀects were generally
minor and self-limiting, and most of them disappeared by
day 7.
4. Discussion
This study addresses drug-resistant malaria, which has
become one of the most important problems in malaria
control in recent years especially as it has been extremely
diﬃcult to develop an eﬀective antimalarial vaccine and
presently there is no single method of control that can
completely eliminate malaria. According to WHO [4], the
ﬁght against antimalarial drug resistance and its future
can be deﬁned by a number of assumptions. First, there
is no control or preventive measure at the moment that
can totally eradicate malaria, so antimalarial drugs will be
needed for a very long time to come. Secondly, so long as
drugs are being used, there is a very high probability for
resistance to develop, and unfortunately the development ofJournal of Tropical Medicine 5
Table 5: Prevalence of anaemia in diﬀerent age groups of patients attending CAMEF during the in vivo study, 2007-2008, during followup
after treatment with Malartin and SP.
Age group (years)
Number of anaemic cases (%)
Day 0 Day 3 Day 7 Day 14
1–5 N = 49 22 (44.90) 18 (36.73) 13 (26.53) 10 (20.41)
6–10 N = 33 06 (18.18) 05 (15.15) 03 (9.09) 01 (3.03)
11–15 N = 24 06 (25.00) 03 (12.50) 02 (8.33) 03 (12.50)
>15 N = 68 06 (8.82) 5 (7.35) 04 (5.88) 03 (4.41)
Total N = 174 40 (22.99) 31 (17.82) 22 (12.64) 17 (9.77)
Level of signiﬁcance χ2 = 21.48,
P<0.001
χ2 = 17.69,
P = 0.001
χ2 = 12.15,
P = 0.016
χ2 = 10.41,
P = 0.034
new drugs seems to be taking longer than the development
of resistance. Aﬀordability remains a very important factor
when considering any strategy to control drug-resistant
malaria, especially in Africa. It is therefore very important to
ﬁnd ways and means to maintain the eﬃcacy of the existing
antimalarial drugs for as long as possible, since prompt
treatment remains the most eﬀective means of control at
the moment. P. falciparum h a sb e e nr e p o r t e dt oh a v ea
complex genome, and is responsible for over 90% of the
malaria cases transmitted in southwest Cameroon [7, 10].
Incomplete parasitological cure may lead to anaemia or
the return of clinical illness which can progress to severe
disease [11]. An optimal antimalarial drug should therefore
succeed in achieving clinical cure, and in clearing parasites
and maintaining a parasite-free period for as long as possible
[4].
In this study, the ACPR at day 14 was 92.53% follow-
ing treatment with Malartin and SP. This study therefore
demonstrated that a combination of Malartin and SP is
good for the treatment of uncomplicated P. falciparum
infection. The observed day 14 ACPR of 92.53% is similar to
results of previous studies in Cameroon, where ACPR with
a combination of artesunate and Fansidar on day 14 was
93.00% [12]; 93.80% for Malartin and amodiaquine [6]a n d
91.7% for artesunate and Fansidar [13].
A clinical treatment failure rate of 07.50% was recorded
in this study and this may be attributed to the presence
of resistant genes (dihydrofolate reductase, dhfr)t oS P .S P
has been widely used in Cameroon as a monotherapy, and
is still available in the saturated pool of antimalarials in
the country. A study by Mbacham et al. [14]i nC a m e r o o n
showed that SP has largely depreciated as a monotherapy.
The combination of SP with artesunate may likely reduce
the rate of emergence of SP and artesunate individual
resistances [15]. Artemisinin derivatives are now the most
potent and rapidly acting antimalarial drugs to which the
malaria parasite is still largely susceptible [16, 17]. Malartin
and SP act essentially as blood schizonticides [4]. Malartin
like other artesunates treats malaria caused by all species
of plasmodia, including multiple drug-resistant strains of
P. falciparum, and is known to be rapidly schizonticidal,
and by suppressing cytokines and the production of tumour
necrosis factor (TNF) helps shorten fever-clearance times
[4,18].Ontheotherhand,SPiseﬀectiveineliminatingfever,
clearing parasitaemia, and improving anaemia in patients
[19]. Despite the development of resistance to SP, it might
be extremely diﬃcult to eliminate the SP monotherapy from
the market as it is cheap, well known, and produced by many
genericdrugproducers.Itisalsowidelyusedforintermittent
preventive treatment in pregnant women in Cameroon.
Other factors that might have contributed to the
observed treatment failure rate could include incorrect
dosing, noncompliance with the duration of the dosing
regimen (since patients had to take the remaining doses of
drugs on their own on subsequent days), drug interaction
and poor or erratic absorption. Perhaps such factors might
have increased the likelihood of parasites being exposed to
suboptimal drug levels [4].
TheprogressivedecreaseinGMPDinourstudyindicated
that the drugs were eﬀective in reducing the parasite load;
there were still some low levels of parasitaemia on day 14 in
a few patients. Perhaps this could be due to reinfection, since
Dibanda is a highly endemic area for malaria. According
to Enevold et al. [20], in malaria endemic areas, children
may recover from malaria after chemotherapy in spite of
harbouring genotypically drug-resistant P. falciparum. This
phenomenon suggests that there is a synergy between drug
treatment and acquired immunity. In high-transmission
areas especially in Africa, the generally accepted objective
of malaria treatment is not so much the clearance of
parasitaemia but the resolution of clinical symptoms and
acute febrile illness as measured by the adequate clinical
response and early and late treatment failures [4].
During followup there was also an amelioration in
PCV levels. This agrees with other studies in Cameroon,
Sudan, Senegal, and Kenya where PCV levels increased
following treatment with ACTs [6, 16, 21]. Anaemia is a very
serious condition, and when associated with malaria causes
morbidity and mortality in young children and pregnant
women in malaria endemic areas. This may imply that P.
falciparum was the major cause of anaemia in the patients,
and it is therefore important to monitor the development
of drug resistance in this area in order to maintain the
therapeutic lifespan of eﬀective drugs for as long as possible.
Repeated episodes of malaria due to reinfection or failure to
clear parasites as a result of antimalarial drug resistance may
result in life-threatening anaemia [22].
In our study, 78.20% of the subjects belonged to the
poor class. Anaemia was found to be more prevalent in
the middle class patients, and interestingly, there was no6 Journal of Tropical Medicine
signiﬁcant diﬀerence in GMPD across the diﬀerent social
classes during followup. This could be due to our relatively
small sample size of the rich and middle classes. This ﬁnding
could be investigated further with a much larger sample size
of the middle and rich classes. It is also worth noting that
a possible selection bias might have occurred in the study
especially at enrolment of the patients. This is evident as
the study subjects were not very representative of the patient
population at large. Maybe, for instance, the presence of
the medical team attracted those patients who had already
suﬀered a treatment failure with drugs they got from drug
stores where patients do not need any medical prescription
to buy drugs and self-medication is common. On the other
hand, the presence of the investigators and the availability
of free diagnostic and treatment facilities during the study
period might have attracted to the clinic patients who would
otherwise not have come for treatment and this is typical of
malaria endemic areas.
Overall, 22.99% (40/174) of the subjects experienced
side eﬀects. This is not surprising as artesunate therapy is
not known to give rise to any serious side eﬀects [6, 16,
21]. SP on the other hand, has several adverse eﬀects like
nausea, vomiting, anorexia, fatigue, dizziness, jaundice, and
diarrhoea, and large doses of SP have also been shown
to cause haemolytic anaemia and agranulocytosis [23]. In
this study, the most frequently reported side eﬀects were
fatigue, fever, and dizziness, and these are symptoms that are
commonwithmalaria.However,mostofthesideeﬀectswere
self-limiting, as most of them disappeared by day 7.
In future, antimalarial therapy may be expanded by
combining chemotherapy with vaccines (or other drugs)
speciﬁcally designed to inhibit transmission of malaria.
These “transmission blocking” vaccines or drugs could
reduce the potential for onward transmission of gametocytes
carrying resistant genes, even if a relatively large number
of parasites survive initial treatment. This could work
through use of drugs or vaccines with a high degree of
speciﬁc antigametocidal activity, drugs that nonspeciﬁcally
reduce the likelihood of gametocytes developing, or drugs
or vaccines that interfere with sexual reproduction and
infection of the parasite within the mosquitoes when taken
up with a blood meal [4].
5. Conclusions
This study has shown that malartin and SP are eﬀective
and safe against uncomplicated falciparum malaria. This
drug combination is therefore a better alternative for the
patients that react to malartin/amodiaquine combination in
Cameroon. One of the cornerstones of the current approach
to malaria control remains the provision of prompt, eﬀective
malaria treatment. Finally, malaria control measures, be
they directed at the vector or malaria parasites in the
human host through mass drug therapy or susceptible
hosts by way of chemoprophylaxis, must be coordinated
by integrating available technology with an understanding
of the epidemiology of the local malaria situation, which
includes a consideration of the behaviour of both humans
and the vector so as to be able to make the most appropriate
and eﬀective interventions.
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